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9.1 Introduction
Increasing prevalence of poorly water‐soluble drugs in pharmaceutical
development provides notable risks of new products demonstrating low and
erratic bioavailability. This dissolution‐limited bioavailability may have
consequences for safety and efficacy, particularly for drugs delivered by the
oral route of administration. Several novel drug delivery technologies have
been developed to improve drug solubility, dissolution rates, and bioavailability. Among those are solid dispersion, nanotechnology, supercritical fluid
technology, lipid‐based technology, and crystal engineering. Although these
strategies are available for enhancing the bioavailability of drugs with low
aqueous solubility, the success of these approaches is not yet guaranteed and
is greatly dependent on the physical and chemical nature of the molecules
being developed. On the other hand, crystal engineering [1] offers a number
of routes such as cocrystallization [2, 3] and coprecipitation [4–6] to improve
solubility and dissolution rate. Coprecipitation of poorly soluble drugs with
polymers, an important technique for improving the dissolution and absorption of drugs, has been modified in recent years to prepare extended‐release
preparations. Previous work on coprecipitation was largely focused on formulation development and product characterization [4–6], for example,
optimization of process variables for the preparation of ibuprofen coprecipitates with Eudragit S100, screening of process and formulation variables for
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the preparation of extended‐release naproxen tablets with Eudragit L100‐55,
and preparation and characterization of coprecipitate of ibuprofen using
different acrylate polymers. It was not until recently that the process analytical
technology (PAT) approach [7–11] was explored to gain insights about the
coprecipitation process and process monitoring.
PAT [7] offered unprecedented opportunities for the pharmaceutical community to take advantage of the availabilities of modern process analyzers and
wealth of experience from other industry sectors. Successful implementation
of PAT can enable real‐time process data acquisition and extract process information and knowledge from real‐time data for better process understanding
and better process control. One of the frequently used technologies for pharmaceutical PAT applications is near‐infrared (NIR) spectroscopy (NIRS). NIRS
is capable of monitoring many pharmaceutical unit operations [9, 10, 12], in
addition to its well‐established pharmaceutical applications in quality control
(QC) and quality assurance (QA) areas [13]. It is a well‐known fact that NIR
spectrum of pharmaceutical material or dosage form is information rich and it
embraces both the physical and chemical information of pharmaceutical material or dosage form [10].
One of the technical challenges for implementing PAT in the pharmaceutical
sector is how to handle the dense flow of process data, including spectra
acquired by real‐time online/in‐line/at‐line process analyzers and process
data acquired by other process measurement techniques. To extract meaningful information from real‐time process data for enhanced process understanding and ultimately process control, one must use chemometrics and process
modeling techniques. Depending on specific systems studied and real‐time
process monitoring techniques implemented, various data analysis and modeling
techniques can be used. Multivariate statistical modeling techniques such as
principal component analysis (PCA) [10, 14, 15], principal component regression (PCR), partial least squares (PLS) [14–16], and artificial neural network
(ANN) [17] are often used to develop a predictive model for depleting raw
material components and/or increasing product components, multivariate
process trajectory, and process map for robust production with optimized
process conditions, productivity, and yield.
Naproxen is a potent nonsteroidal anti‐inflammatory drug used in the
treatment of rheumatoid arthritis, osteoarthritis, and acute gout and as
analgesic and antipyretic. However, its use is frequently limited due to significant gastrointestinal side effects. In this study, naproxen was selected as
a model drug as it has a short half‐life, has gastrointestinal effects, is soluble
in alcohol, and is practically insoluble in water. The literature data for the
experimental and predicted solubility of naproxen in water are 15.9 and
51.0 mg/l, respectively (http://www.drugbank.ca/drugs/DB00788, accessed
on April 16, 2010). Eudragit L100 is the commercial name of an enteric
polymer of methacrylic acid–methylmethacrylate that belongs to a class of
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reversible soluble/insoluble polymers. Eudragit L100 was used as it yields
coprecipitates with naproxen without any need of additives. The dynamic
coprecipitation process designed in this work was proceeded via gradually
introducing water to the ternary system of naproxen–Eudragit L100–alcohol at
controlled temperature of 25°C. When water is introduced into the initially
transparent ternary solution sequentially, the overall composition point of
naproxen–Eudragit L100–alcohol–water system will be moved accordingly
within the phase diagram. Due to significant difference of solubility in
alcohol and water for both naproxen and Eudragit L100, the naproxen–
Eudragit L100 coprecipitates out from the solution when water is introduced. As a result of the coprecipitation phenomena, the initial transparent
solution of the four‐component system will become cloudy at the onset of
nucleation. In this work, an integrated PAT real‐time monitoring strategy
was developed to follow the dynamics of the coprecipitation process. As
discussed previously, the real‐time in‐line data acquired can help to illustrate
the progress of a multiphase process and to elaborate the sequential events
that take place during the process [9]. In this work, multivariate process
trajectory was constructed based on the real‐time process monitoring data
sets, which would be helpful for achieving rational particulate process design
and ultimately particulate process control.

9.2 Experimental
9.2.1 Materials

Naproxen USP was obtained from Albemarle Corporation (Orangeburg, SC).
It is an odorless, white to off‐white crystalline substance. Eudragit L100 was
obtained from Röhm America Inc. (Somerset, NJ). It is a white powder with a
faint characteristic odor. Solvent reagent alcohol (HPLC grade) was purchased
from Fisher Scientific. Nonsolvent DI water was obtained from a FDA in‐house
facility and was kept in refrigerator at 4°C prior to use. All of these chemicals
and solvents were used without any further processing or purification prior to
the use for this experimental work.
9.2.2 Equipment and Instruments

Process NIR spectra were acquired with a LuminarTM acousto‐optic tunable
filter (AOTF)‐based NIR process spectrometer (Brimrose Corporation of
America, Baltimore, MD), equipped with a transflectance probe. This AOTF
NIR process spectrometer has the capability of in‐line monitoring both the
changes in the concentration of the key components and phase changes in the
coprecipitation system or subsystems. The acquisition parameters of Brimrose
NIRS being used in experiment included the following: the number of spectra
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average was 50; no background correction was applied; normal scan type; and
the gain was 2. One spectrum was recorded and saved automatically every 6 s.
A 1.0 cm probe extension was attached to the 679B dark‐field diffuse reflectance/
transmission probe for the actual process monitoring.
Online turbidity measurements were made using a Model 2100AN
Laboratory Turbidimeter (Hach Company, Loveland, Colorado) with a
Masterflex® L/S® model 7518‐10 digital fluid pump (Cole Parmer Instrument
Company, Chicago, IL). A flexible tubing connection between the coprecipitation vessel and the sample flow cell of the turbidimeter was made, such that the
fluid could be pumped from the coprecipitation vessel to the sample flow cell
of the turbidimeter for online turbidity measurement and then be returned to
the coprecipitation vessel in the reverse direction. Prior to its use for this work,
the 2100AN turbidimeter was calibrated using formazin stock solution as
recommended by the supplier. Data were reported using nephelometric
turbidity units (NTU), which are specifically compliant for a 90° measurement
technique.
Pure components of naproxen and Eudragit L100 were scanned by FOSS
NIRsystems (Foss NIRsystems, Silver Spring, MD) offline. The schematic of
the experimental setup is shown in Figure 9.1. As shown in Figure 9.1, among
many important formulation and process variables, only the drug/polymer
ratio was changed during the coprecipitation experiment of this study, while

Nonsolvent

Turbidimeter

AOTF
Brimrose
spectrometer

Pump

Turbidity

NIR

Important process variables
-slurry temperature (fixed)
-stirring rate (fixed)
-water addition rate (fixed)
Important formulation variables
-drug/polymer ratio (change)
-solvent selection (alcohol)
-nonsolvent selection (water)

Data analysis and modeling
Coprecipitation vessel

Figure 9.1 Schematic diagram of experimental setup and process flow with an integrated
PAT monitoring system for API (naproxen)/polymer coprecipitation process using in‐line
process NIR and online turbidity measurement simultaneously.
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others were fixed. For terminologies about in‐line/at‐line/online definitions
can be found in the FDA PAT guidance [7].

9.3 Data Analysis Methods
9.3.1 PCA and Process Trajectory

PCA is a very useful tool as it can reduce the dimensionality of a data set consisting of a large number of interrelated variables while retaining as much as
possible the variation present in the data set. PCA has been extensively applied
in almost every discipline, such as chemistry, biology, engineering, meteorology, and pharmaceutical. It can be used in process monitoring, QC, data visualization, batch trajectories, and other areas. For pharmaceutical QbD and
PAT applications where process analyzers are installed, frequently a huge
amount of interrelated process data has to be handled, in a way that critical
process information and knowledge can be extracted for both process and QC
purposes. Therefore, PCA is a powerful chemometric technique for such
applications. With the help of PCA, the following aspects could be examined:
in what aspect one sample is different from another, which variables contribute
most to this difference, and whether those variables contribute in the same way
(i.e., are correlated) or independently of each other. It can also help to detect
patterns and to quantify the amount of useful information, as opposed to noise
or meaningless variation, contained in the data set. In this work, plots of a PC
versus another (e.g., PC1 vs. PC2), called score plot, are used to depict the
process trajectory. Process trajectory method has been used for batch process
supervision [18], process monitoring, and diagnosis [19] in chemical and biotech sectors. However, relatively few applications have been reported for pharmaceuticals, especially for small molecule drug manufacturing process
monitoring and process control [20]. In this work, all of the NIR spectra were
acquired for the wavelength range of [1100, 2300] nm. PCA was conducted on
raw NIR spectra without any preprocessing in all cases.
9.3.2 Singular Points of a Signal

It has been noticed that for a time‐varying signal in a dynamic system, the information content is not homogeneously distributed throughout [21]. Some landmarks such as extreme values and shape changes in the data, termed as singular
points (SPs), in the process trajectory contain more information about the
dynamic behavior than others. Mathematically, a singularity is in general a point
at which a given mathematical object is not defined or a point of an exceptional
set where it fails to be well behaved in some particular way, such as differentiability. Therefore, for a differential equation, an SP is a point that is a singularity
for at least one of the known functions appearing in the equation. Geometrically,
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an SP is a point (ii) on a curve at which the curve possesses no smoothly turning
tangent, or crosses or touches itself, or has a cusp or isolated point, or (ii) on a
surface whose coordinates, x, y, and z, depend on the parameters u and v, at
which the Jacobians D(x, y)/D(u, v), D(y, z)/D(u, v), and D(z, x)/D(u, v) all vanish.
The property of singularity and SP could be very useful for many important
engineering applications such as rational process design and process control.
For example, SPs are used to segment the process signal into regions with
homogeneous properties. Because SPs have physical meaning such as beginning or ending of a process event, they can be directly used for state identification, process monitoring, and process supervision. Examples of SPs include
points of discontinuities, trend changes, and extrema. SPs were used to detect
phase shifts during rifamycin B fermentation experiments [22] and to characterize microscopic flows [23]. In our previous works, SPs were used to determine powder blending process end point [15] and phase change during a
coprecipitation process [9]. In this work, SPs are used to detect the onset of
nucleation and crystal growth and to establish the process transition window.
In the area of multivariate data analysis and modeling under the pharmaceutical QbD/PAT framework, it is important to recognize the difference between
SP and outlier. In multivariate statistics, an outlier is an observation that is
numerically distant from the rest of the data. Outliers can occur by chance in
any distribution, but they are often indicative either of measurement error or
that the population has a heavy‐tailed distribution. Outliers may be indicative
of data points that belong to a different population than the rest of sample set.
The commonly used method for identifying outliers in multivariate analysis is
based on the squared Mahalanobis distance (MD) [24]. Points for which MD2
value is large are identified as atypical or outliers and evaluated using the χ2
distribution with the appropriate degrees of freedom. SP, as discussed earlier, is
in general a point at which a given mathematical object is not defined or a
point of an exceptional set where it fails to be well behaved in some particular
way, such as differentiability. Therefore, mathematically outlier and SP are two
totally different concepts; physically, they have different meanings that are
related to different properties.

9.4 Results and Discussion
To investigate the utility of process trajectory for pharmaceutical process monitoring, a step‐by‐step approach was taken. First, we examined simple cases of
binary systems for which either two dry powder components or two liquid components are involved. The NIRS was used for process assessment and process
monitoring of the binary systems. Then, we examined a complicated system of
four‐component coprecipitation process (both solid and liquid phases are
involved) for which NIRS was used for real‐time in‐line process monitoring.
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9.4.1 Using Offline NIR Measurement to Characterize the
Naproxen–Eudragit L100 Binary Powder Mixing Process

The binary systems of naproxen–Eudragit L100 with various ratios of Eudragit
L100 over Naproxen (E/N ratio) were mixed and assessed by FOSS NIRS. The
blending end point was determined by the STDEV method described in our
previous work [15]. Care was exercised to ensure the sufficient homogeneity
for the blends and the sampling representativeness. Only the NIR spectra of
the final well‐blended binary mixtures at each E/N ratio were used for the
PCA. It was found that PC1 and PC2 can explain 98 and 2% of the total variability captured by the NIR spectra, separately. As shown in Figure 9.2, process
trajectory depicted by the PCA score plot demonstrated three distinct segments or clusters that can be approximated by three straight lines:
1) The leftmost segment starts with pure component of naproxen and is a cluster
of binary blends dominated with naproxen. In addition, the plot of PC2 score
versus PC1 score has a positive slope. Furthermore, the higher the Eudragit
L100–naproxen ratio, the larger the scores of both PC1 and PC2. However, the
situation in the vicinity of the transition is complicated. As expected, the PC2
score value for point E/N = 0.257 is larger than that for point E/N = 0.206. This
follows the trend displayed by other three points (E/N = 0, 0.098, 0.113).
0.60
E/N = 3.734

0.50
0.40

PC2 score

0.30

E/N = 0.257

0.20

E/N = 0.206

0.10

E/N = 422.864
E/N = 543.074

E/N = 0.113

E/N = 250.602

0.00
E/N = 0.098

–0.10

E/N = 842.729

–0.20
–3

–2.5

–2

E/N = 38.581
E/N = 10.02
E/N = 336.908

Naproxen (E/N = 0)

–0.30

E/N = 91.863

E/N = 1.843 E/N = 18.833

Eudragit L100

–1.5

–1
–0.5
PC1 score

0

0.5

1

1.5

Figure 9.2 PCA‐based process trajectory for binary powder blends of naproxen and
Eudragit L100. The binary powder blends were made by mixing naproxen and Eudragit
L100 with various weight ratios as shown in the figure by E/N values. After mixing well, the
blends were transferred to vials that were then scanned by FOSS NIRS offline. The PCA was
conducted on NIR spectra of the binary blends with various E/N values.
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However, the absolute PC1 score value for point E/N = 0.257 is a bit smaller
than that for point E/N = 0.206. This does not follow the trend exhibited by
other three points. Possible factors that may attribute to this situation include
(i) abnormal powder behavior in the vicinity of transition point, such as local
inhomogeneity due to back‐mixing, and (ii) experimental error.
2) The second segment links the leftmost segment and the rightmost segment,
which is a cluster of binary blends dominated by either naproxen or Eudragit
L100, respectively. In addition, the plot of PC2 score versus PC1 score has a
negative slope.
3) The third segment is on the rightmost, starts with the pure component of
Eudragit L100, and is a cluster of binary blends dominated by Eudragit L100.
The plot of PC2 score versus PC1 score has a positive slope. It was found
that apparently the sign change of the slope for the plot of PC2 score versus
PC1 score might be linked to the NIR detection limit of each component in
the binary mixture. That is, when the actual weight (mole) fraction of one
component is decreased to such an extent that it becomes a minor component in the binary mixture, the signal of the minor component becomes so
weak that the presence of the minor component cannot be evidenced solely
and directly by examining the NIR raw spectra of the blends. As demonstrated in this case, the process trajectory based on PCA score plots has the
capability of differentiating the information embedded. For example, it is
able to distinguish when the dominant source of contributing component is
switching, as demonstrated by the second segment in Figure 9.2. The second
segment serves as a process transition window.
9.4.2 Using In‐Line NIR Spectroscopy to Monitor the Alcohol–Water
Binary Liquid Mixing Process

In‐line NIRS was used to monitor the binary mixing process of alcohol and
water in real time. Alcohol and water with various volume ratios were mixed
and homogenized. The mixing process was monitored using in‐line NIRS. The
NIR spectra of the well‐mixed binary mixture were complied as an NIR data set.
PCA was then applied to this data set. It was found that PC1 and PC2 account
for 98 and 2%, respectively, of the total variability embedded with the NIR spectra of the binary mixtures. As shown in Figure 9.3, process trajectory depicted
by the PCA score plot demonstrated that there is a process transition window
where the slope of the plot of PC2 score versus PC1 score changes from positive
to negative. The left segment starts with pure component of alcohol and consists of a cluster of alcohol‐dominant binary solutions. When water is gradually
introduced into alcohol, the scores of both PC1 and PC2 increase. In contrast,
the right segment starts with pure component water and consists of a cluster of
water‐dominant binary solutions. When alcohol is gradually introduced into
water, the PC1 score is decreased, while the PC2 score is increased. Furthermore,
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Figure 9.3 PCA‐based process trajectory for binary liquid mixtures of alcohol and water
with various volume ratios at room temperature. The binary liquid mixtures were made by
mixing alcohol and water with various volume ratios. After mixing well, the blends were
measured by real‐time Brimrose in‐line NIR spectroscopy. The PCA was conducted
on NIR spectra of the binary blends with various alcohol/water ratios.

it was found that apparently the sign change of the slope for the plot of PC2
score versus PC1 score is linked to the NIR detection limit of each component
in the binary mixture. When the actual weight (mole) fraction of one component is decreased to such an extent that it becomes a minor component in the
binary mixture, the signal of the minor component becomes so weak that the
presence of the minor component cannot be evidenced solely and directly by
examining the NIR raw spectra of the blends. However, apparently the process
trajectory based on PCA score plots helps to differentiate the information
embedded. In other words, the switching of the dominant source of contributing component is demonstrated by the process transition window in Figure 9.3.
As in this case, the inhomogeneous nature of the information embedded as well
as the discontinuity exemplified by the sign change of the slope in the process
trajectory collectively evidenced the existence of an SP.
9.4.3 Real‐Time Integrated PAT Monitoring of the Dynamic
Coprecipitation Process

When the number of components involved in a multicomponent system is
increased, typically the process complexity is increased accordingly. In this
subsection, two aspects will be explored: (i) if a similar methodology can be
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used to develop the process trajectory and (ii) if the PCA‐based process
trajectory can reveal critical process events such as nucleation and growth.
9.4.4 3D Map of NIR Absorbance–Wavelength–Process Time
(or Process Sample) of the Coprecipitation Process

When in‐line NIRS is applied to pharmaceutical unit operations, a lot of process‐
related information may be captured in real time. For the dynamic coprecipitation process evaluation, prior to the introduction of the nonsolvent
(water) to the coprecipitation vessel, there was a ternary system of naproxen–
Eudragit L100–alcohol already present in the vessel. When water is gradually
introduced into the vessel, according to classical thermodynamics, the overall
composition point in the four‐component system phase diagram is moved
from the liquid phase toward the solid (crystal)–liquid equilibrium line; the
zone that is bordered by the solid–liquid equilibrium line (the solubility curve)
and the metastable limit constitutes the metastable zone for coprecipitation.
The graphical illustration of the movement of equilibrium line and metastable
zone is shown in Figure 9.4. Once the solid–liquid equilibrium line is crossed,
coprecipitate begins to form and grow. The overall composition point will be
located within the solidus region. As discussed later, the three‐dimensional
(3D) process map can illustrate how the coprecipitation process progress and
what process events occur during the process.
Concentration, C
Metastable limit

Solubility curve
C2

C

C1
C0

B

E

A

F
D

Tlim

T1

T2

Temperature, T

Figure 9.4 Graphical illustration of the movement of equilibrium line and metastable line
zone. Concentrations C0, C1, and C2 represent the solubility of solute at temperature
Tlim, T1, and T2, respectively.

Quality by Design: Process Trajectory Development for a Dynamic Pharmaceutical Coprecipitation

To enhance the resolution of the 3D process map for identifying process
s ignatures, the addition rate of the nonsolvent into the system was kept slow,
such that the transition of one process state to another state could be observed
clearly. The formulation components used, the amount of the nonsolvent
added and its adding sequence, and significant visual observations or indications from turbidity measurement are summarized in Table 9.1. As one example, the process 3D (NIR spectral number–wavelength–NIR absorbance) map
for batch started with formulation components of 4.7617 g naproxen and
1.205 g Eudragit L100 (batch code (a) in Table 9.1) is shown in Figure 9.5.
9.4.5 Process Signature Identification

The 3D process map is able to provide visual evidence about significant process event for the ongoing process, such as addition of a new component into
the existing system, depletion of an existing component, etc. The sensitivity
and resolution of this kind of 3D direct and raw process map depend on a
number of factors such as (i) the sensitivity and resolution of the instrumentation and the signal/noise ratio of the instrumentation used, (ii) the mass transfer rates in the vicinity of process probe tip and the bulk solution in the vessel,
and (iii) the hydrodynamics of the fluid and mixing characteristics in the vicinity of water dispersion area inside the vessel. The physical distance between the
process probe tip and the point where the nonsolvent water is introduced and
in contact with the bulk solution presents a factor to limit the mass transfer
process. In our study, despite the fact that the magnetic stirring of the solution
could limit the possible concentration gradient within the vessel eventually, the
time lag between the initial moment when the process event take places locally
and the moment when the process probe is able to actually detect is always
unavoidable due to the existence of physical distance. When a signal associated
with a process event is relatively weak, especially when the process event is at
its embryo stage, its appearance on the 3D process map will not be that obvious. In this case, other tools may be needed for magnifying or identifying the
signature. Furthermore, there are some important questions associated with
the 3D process map to be answered. Questions include but are not limited to:
(1) What are the implications of the inflection points in the 3D map? (ii) Is
there any new phase formation during the process? In this case, other techniques such as chemometrics may play a vital role in terms of identifying process signature associated with process event and provide essential information
regarding process progression. In this work, PCA was applied to the process
NIR spectra to construct process trajectory and identify SPs such that critical
process information and knowledge could be extracted.
Applying PCA to the process NIR spectra of the aforementioned process
batch showed that two principal components are sufficient to characterize the
variability embedded with NIR spectra. PC1 and PC2 are able to account for
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Table 10.1 Risk assessment of the blending process step using FMEA according to Adam et al. [1].

Effect

Varying content
uniformity of final dosage
form

Severity
(S)

5

Failure mode

Inhomogeneity of
final blend

Detectability
(D)

4

Probability
(P)

RPN

Particle‐size ratio

5

100

Weight ratio

5

100

Particle shape

5

100

Cohesivity

5

100

Material density

4

80

Fill volume

4

80

Blending time/total
revolutions

5

100

Blend rpm

1

20

Order of addition

3

60

Equipment
design

Blender type

4

80

Blender total
volume

3

60

Environment

Relative humidity

3

60

Temperature

2

40

Cause

Raw material
properties

Process
parameters

Five‐point scales for S, D, and P, with 5 as worst‐case value and 1 as best‐case value, are used. An RPN of 50 is defined as the cutoff limit.
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Figure 9.5 Three‐dimensional map of the process state over the entire process course of
adding water to the ternary system. An inflection point occurs among process spectra
window between spectral numbers #60 and #67. New phase is detected between spectral
numbers #60 and #67, which maybe an indication of nucleation and growth.
3
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Figure 9.6 PCA score plot for process NIR spectra of the process batch started with
formulation components of 4.7617 g naproxen and 1.205 g Eudragit L100.

93 and 7%, respectively, of the total variability embedded with the process NIR
spectra for this batch. As shown in Figure 9.6, when PC2 score is plotted against
PC1 score, there is a sharp transition on its PCA score plot as reflected by the
change in the slope of the straight line of PC2 score versus PC1 sore. The slope
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is dramatically changed from positive value to negative value. As a matter of
fact, the two segments of the process trajectory consisting of PC2 score versus
PC1 score are almost perpendicular to each other. When tracking the sample
number or NIR spectral number on this PCA score plot, it was found that
(i) the process trajectory that has positive slope value corresponds to the
process state of transparent solution during the course of adding water into
the ternary system, (ii) the sharp transition of the process trajectory corresponds
to the period that solution starts to become cloudy when water is introduced to
the ternary system for the third time, and (iii) the process trajectory that has
negative slope value corresponds to the process state of cloudy solution during
the course of adding water into the ternary system.
The process trajectory depicted by the PCA score plot demonstrated that
certain process samples #61–66 can be identified, which cover the process
transition window where nucleation and growth take place, as supported by
both visual evidences and real‐time turbidity profile of the dynamic coprecipitation process. In order to further verify this finding, similar data analysis
method was extended to dynamic coprecipitation processes that have different
drug/polymer ratios in the starting formulation preparation. In‐line NIRS was
used to monitor the dynamic coprecipitation process in real time for various
batches with different drug/polymer ratios. PCA was applied to each NIR
spectra data set associated with a particular drug/polymer ratio. Process trajectory for each coprecipitation process was constructed based on the PCA
results. These results together with our previous work [9] collectively demonstrated that process trajectory based on online NIR real‐time process monitoring and PCA can differentiate various distinguishable process events and
accurately track various process stages such as incubation, nucleation, and
crystal growth.
9.4.6

Online Turbidity Monitoring of the Process

For the process runs being conducted in this work, we also used online turbidity measurement to monitor the turbidity change real time during the process.
The real‐time process slurry turbidity profile of a dynamic coprecipitation
process (batch code (b) in Table 9.1) is shown in Figure 9.7. As we can see from
Figure 9.7, there are several plateaus observed during the course of introducing
water into the ternary system. Before adding any water to the ternary system,
the baseline turbidity data of the ternary system were around 0.33–0.45 NTU.
The first plateau (1.7–2.6 NTU) and the second plateau (50–70 NTU) correspond to the first and the second addition of 100 ml of water into the ternary
system, respectively. The third plateau (140–150 NTU) occurred due to third
addition of 100 ml of water into the ternary system. Given that the turbidity
value of first plateau of the four‐component system is still very close to the
baseline turbidity value of the ternary system, most likely it indicates that
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Figure 9.7 Turbidity profile during the process of sequentially adding water to the ternary
system of API (0.1320 g), Eudragit L100 (6.0970 g), and alcohol (320 ml) to form the
coprecipitate.

the system remains as transparent solution and no new phase is formed
(as confirmed by the online process NIR monitoring). The relative low turbidity values for the second turbidity plateau suggest that the process is still at the
incubation stage. At this early stage, the composition point of the system is still
located within the liquid region. Therefore, no nuclei were formed and the
solution was still transparent and thus had a small NTU value. When more
water was introduced gradually, the third turbidity plateau (140–150 NTU)
occurred, which is probably correlated with the nucleation process stage. At
this stage, the system composition point reaches the solid–liquid equilibrium
line, and thus nuclei were initiated and a bit higher turbidity values than
the second stage were detected. Afterward, when more water was introduced,
the system composition point reaches the metastable zone. Consequently, a
large supersaturation was created and a crystal growth period was observed.
This stage has a turbidity plateau of 2360–2770 NTU. When more and more
water was introduced, the system approaches a quasi‐steady state where an
even higher turbidity plateau of 4000–5180 NTU was observed.
The aforementioned experimental observations could be explained from a
multiphase transfer perspective. When water was introduced into the ternary system initially, there were some small nuclei formed initially in the
vicinity of the water dispersion area due to local building up of supersaturation; then, the newly formed local nuclei were dissolved quickly due to the
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de‐supersaturation phenomena via mass transfer (diffusion and convection)
enhanced by the magnetic stirring of the slurry solution. However, since the
existence of fine nuclei was so short and did not have sufficient time to travel
to the area that was directly exposed to the process NIR probe tip, this short
shelf‐life nuclei was not detected by the Brimrose Process NIRS system. The
relative high turbidity values for the third turbidity plateau (140–150 NTU)
plus the visible slightly cloudiness of the solution suggest that the process is
at the nucleation stage. At this stage, the system composition point reaches
the solid–liquid equilibrium line, and thus nuclei were initiated and a bit
higher turbidity values than the second stage were detected. When more
water was introduced gradually, the fourth turbidity plateau (2360–2770
NTU) occurred, which is probably correlated with a stage that both nucleation and crystal growth are involved since the system composition point
reaches the metastable zone. Afterward, when more water was introduced,
consequentially, a large supersaturation was created and a crystal growth
period was observed.

9.5 Challenges and Opportunities for PCA‐Based
Data Analysis and Modeling in Pharmaceutical
PAT and QbD Development
PCA is a popular and powerful technique for feature extraction and dimensionality reduction and probably one of the most employed techniques of multivariate analysis. Maggio et al. reported a new PCA‐based approach for testing
“similarity” of drug dissolution profiles [25]. Comparison between the area
enclosed by the confidence ellipses of the weighted scores plot and the region
obtained from the bootstrap‐calculated acceptable values of the corresponding
f2 tests suggested that PCA confidence region represents, in general, a more
discriminated standard. Otsuka et al. used PCA for identifying and predicting
the most important variables in the process of granulation and tableting [26].
However, there are some limitations with PCA that we should take into consideration, which include the following: (i) the absence of an associated probability density or generative model; (ii) the subspace itself is restricted to a linear
mapping as PCA is a linear method; and (iii) PCA does not reveal any reliable
information on time scales that are not actually sampled [27] (e.g., a short
molecular dynamics trajectory does not yield an accurate covariance matrix of
protein fluctuations). The high‐order statistical information is discarded during the linear mapping. Basically PCA involves rotating the ellipsoid in such a
way that the direction of the variance of the data comes as the first component.
This works fine as long as the X/Y relation is fairly linear. For a situation where
the X/Y relation is nonlinear, there is a problem. While PCA still tries to produce components by variance, it fails as the largest variance is not along a
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single vector, but along a nonlinear path, with the assumption that the observed
data is independent. In real‐world process measurement environment, this
may not be a valid assumption due to the facts that (i) the measurement data at
consecutive time points could be interrelated and (ii) NIR absorbance values at
nearby wavelengths could be correlated too. If a system is highly nonlinear or
the observed data are not independent, then the limitations of PCA‐based
process trajectory become a problem. In this challenging case, other methods
may provide better option to handle the nonlinearity encountered, as discussed
in the following text.
A number of strategies have been proposed to address the aforementioned
limitations of PCA. For example, probabilistic principal component analysis
(PPCA) [28], kernel principal component analysis (KPCA) [29], and probabilistic kernel principal component analysis (PKPCA) [30–32] have been developed
to deal with the first two limitations of PCA. In addition, a hidden Markov
model (HMM) [33] was used to obtain an optimized representation of the
observed data through time. On the other hand, neural networks [17, 34] are
perfectly capable of dealing with nonlinear problems and can on their own do
this. Furthermore, they can do scaling directly so that the principal components can be scaled by their importance.
In the pharmaceutical manufacturing setting, it is possible to encounter
nonlinear process features due to many variables (such as formulation variables, process variables, environmental variables, etc.) coexisting and possible interactions. Risk analysis and risk assessment [35] may help to rank
the relative importance of those variables and thus provide a list of critical
variables for further scientific investigation and design space development
[17]. On the other hand, depending on the ranges of various variables
selected, the impact of interaction among variables could be significant,
marginal, or insignificant. This can be quantitatively assessed via design of
experiments (DOE) and ANOVA, as illustrated previously [17]. For those
critical variables identified via risk analysis and initial DOE study mentioned earlier, another DOE could be conducted to establish the linkage
between critical variables and essential response variables (such as key
quality attributes) as demonstrated in most DOE‐based approaches. Or, as
demonstrated in our recent work, an integrated PAT and DOE approach
can be developed to establish dynamic linkages between the real‐time process behaviors and the essential response variables at both transition state
and steady state [17]. Both approaches are important to ensure product
quality and help to achieve QbD.
The PCA‐based process trajectory is useful to diagnose process healthiness and identify outliers and abnormal situations. However, the applicability of the PCA‐based process trajectory for this kind of process QC and
process QA really depends on the scope of the design space [36, 37] (formulation and process variables) investigated, for which the process trajectory

251

252

Comprehensive Quality by Design for Pharmaceutical Product Development and Manufacture

was based on. Therefore, it is important to have a clear understanding of
where and when PCA‐based process trajectory can be applied for process
control purpose and of how robust the PCA‐based process trajectory is to
the process disturbance in real applications, especially for the cases where
events and disturbances appear in many different time scales. Issues surrounding PCA‐based process trajectory, design space development, PAT
process monitoring and control strategies, and QbD methodologies, as discussed briefly in this section, deserve much attention in future research and
development during the implementation of PAT [7, 37] and QbD [7, 36–39]
in the pharmaceutical sector.

9.6 Conclusions
This work provides a QbD case study that focuses on process trajectory development for a dynamic pharmaceutical coprecipitation process based on an
integrated real‐time PAT process monitoring strategy. The dynamic coprecipitation process is visualized via three‐dimensional map of NIR absorbance–
wavelength–process time. The process trajectory based on the results of
applying PCA to real‐time process NIR spectra data clearly demonstrated that
physical meanings can be assigned to various SPs that occurred. Furthermore,
those SPs in the process trajectory are directly linked to various distinguishable
process events and process signatures such that incubation, nucleation, and
crystal growth could be accurately tracked and differentiated. This information
and knowledge are essential for developing a suitable design space and operational process space for a pharmaceutical unit operation. The challenges and
opportunities of PCA‐based process trajectory under the PAT framework and
ICH Q8(R2) have been discussed.
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